FierceBiotechOriginal article
{"a":[{"_":"Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal","$":{"href":"/biotech/dimerix-snaps-missions-stalled-phase-2-ready-kidney-disease-candidate-5m-upfront","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Dimerix acquired an acute kidney injury drug candidate from Mission Therapeutics for $5 million upfront plus up to $287 million in milestone payments. The phase 2-ready asset addresses kidney disease.
Clinical Trial Data
Phase
Phase 2
Importance:7/10
Sentiment:
0.60
M&Akidney diseaseacute kidney injuryPhase 2milestone payments
Read the original article
Published by FierceBiotech on July 17, 2026 4:52 AM